IGFBP-3 blood test
Insulin-like growth factor binding protein 3. Also called: IGF binding protein 3, IGF-BP3
IGFBP-3 is the main protein that carries IGF-1 in the blood. Like IGF-1 it follows growth hormone, so it is used alongside IGF-1 in growth disorders. Normal ranges depend on age, sex and the lab's assay.
At a glance
| What it measures | IGFBP-3, the main protein that carries IGF-1 in the blood. Its level follows growth hormone. |
|---|---|
| Sample | Blood (serum). Neither Labcorp nor ARUP lists fasting. |
| Typical adult range | Depends on age, sex and lab. Labcorp, ages 41-45: men 2,515-6,018 ng/mL, women 2,409-5,610 ng/mL. |
| Peptides that move it | Raised by MK-677 (Ibutamoren) and Tesamorelin in trials. Lowered by Lanreotide. Hexarelin did not change it over 16 weeks. |
| Lab code | LOINC 2483-6 (Labcorp 140152, ARUP 0070060) |
What is IGFBP-3?
IGFBP-3 (insulin-like growth factor binding protein 3) is the most abundant of the six proteins that carry IGF-1 and IGF-2 in the blood. Together with IGF-1 and a third protein, the acid-labile subunit, it forms a large complex that holds most circulating IGF-1.
Labs measure it in the investigation of growth hormone deficiency, acromegaly and hypopituitarism, and to monitor growth hormone treatment, usually alongside IGF-1.
How it is made and regulated
Where it is made
Children with liver damage from biliary atresia had low IGFBP-3, which suggests the liver is a major source. In the original radioimmunoassay study, healthy adults averaged 6.12 µg/mL, and levels fell with age.
What controls it
Growth hormone is the main driver: IGFBP-3 tracked overnight GH secretion (r = 0.62), was 2.2 times higher in active acromegaly, and was 50-80% lower in GH deficiency. Nutrition matters too: a 3-day fast lowered it by 16%. Thyroid hormone also raises it, separately from GH.
How it travels in the blood
IGFBP-3 binds IGF-1 and IGF-2 very tightly, about one IGF molecule per IGFBP-3. With the acid-labile subunit it forms a three-part complex that carries 75-90% of circulating IGF-1; the Increlex label puts it at more than 80%. All three parts of the complex depend on growth hormone.
How long it lasts
IGFBP-3 levels stay constant over 24 hours and respond slowly to growth hormone, so a single result reflects GH activity over several days. IGF-1 held in the large complex lasts 12-15 hours, against 10-12 minutes for free IGF-1.
What it does
By holding IGF-1 in the circulation, the complex extends its half-life and blocks its blood-sugar-lowering effect.
Sources: [1]
Reference ranges
Each lab sets its own ranges for its own assay, so the two tables below do not match. Use the range printed on your report.
Labcorp (test 140152)
Adults
| Age | Male (ng/mL) | Female (ng/mL) |
|---|---|---|
| 18 | 2678-6327 | 2749-6510 |
| 19 | 2700-6341 | 2779-6527 |
| 20 | 2723-6361 | 2809-6550 |
| 21-25 | 2753-6361 | 2855-6559 |
| 26-30 | 2683-6127 | 2752-6219 |
| 31-35 | 2610-5977 | 2573-5804 |
| 36-40 | 2571-5982 | 2504-5709 |
| 41-45 | 2515-6018 | 2409-5610 |
| 46-50 | 2374-5891 | 2343-5612 |
| 51-55 | 2251-5808 | 2306-5703 |
| 56-60 | 2133-5711 | 2238-5717 |
| 61-65 | 2027-5610 | 2161-5691 |
| 66-70 | 1926-5487 | 2059-5572 |
| 71-75 | 1779-5201 | 2005-5549 |
| 76-80 | 1673-5015 | 1950-5490 |
| 81-85 | 1632-5014 | 1925-5498 |
| 86-90 | 1665-5239 | 1961-5672 |
| >90 | Not established | Not established |
Children and teens
| Age | Male (ng/mL) | Female (ng/mL) |
|---|---|---|
| 0-11 months | 1113-3180 | 1053-3271 |
| 1 | 1289-3634 | 1221-3721 |
| 2 | 1465-4074 | 1388-4151 |
| 3 | 1637-4492 | 1553-4557 |
| 4 | 1801-4878 | 1713-4933 |
| 5 | 1942-5193 | 1854-5242 |
| 6 | 2039-5384 | 1945-5403 |
| 7 | 2096-5466 | 2019-5515 |
| 8 | 2153-5550 | 2096-5629 |
| 9 | 2221-5660 | 2180-5762 |
| 10 | 2300-5801 | 2270-5908 |
| 11 | 2385-5956 | 2360-6055 |
| 12 | 2463-6093 | 2444-6184 |
| 13 | 2528-6198 | 2517-6286 |
| 14 | 2580-6272 | 2580-6365 |
| 15 | 2614-6306 | 2636-6428 |
| 16 | 2638-6316 | 2682-6470 |
| 17 | 2657-6319 | 2718-6495 |
Labcorp reports results in µg/L, which is numerically the same as ng/mL. No range is set above 90.
ARUP Laboratories (test 0070060)
| Group | Range (ng/mL) |
|---|---|
| 18 years | 3100-7900 |
| 19 years | 2900-7300 |
| 20 years | 2900-7200 |
| 21-25 years | 3400-7800 |
| 26-30 years | 3500-7600 |
| 31-35 years | 3500-7000 |
| 36-40 years | 3400-6700 |
| 41-45 years | 3300-6600 |
| 46-50 years | 3300-6700 |
| 51-55 years | 3400-6800 |
| 56-60 years | 3400-6900 |
| 61-65 years | 3200-6600 |
| 66-70 years | 3000-6200 |
| 71-75 years | 2800-5700 |
| 76-80 years | 2500-5100 |
| 81-85 years | 2200-4500 |
| 86 years and older | Not established |
Children and teens
| Group | Range (ng/mL) |
|---|---|
| 0-7 days | 500-900 |
| 8-14 days | 500-1400 |
| 15 days-11 months | Not available |
| 1 year | 700-3600 |
| 2 years | 800-3900 |
| 3 years | 900-4300 |
| 4 years | 1000-4700 |
| 5 years | 1100-5200 |
| 6 years | 1300-5600 |
| 7 years | 1400-6100 |
| 8 years | 1600-6500 |
| 9 years | 1800-7100 |
| 10 years | 2100-7700 |
| 11 years | 2400-8400 |
| 12 years | 2700-8900 |
| 13 years | 3100-9500 |
| 14 years | 3300-10000 |
| 15 years | 3500-10000 |
| 16 years | 3400-9500 |
| 17 years | 3200-8700 |
| Tanner stage I, boys | 1400-5200 |
| Tanner stage I, girls | 1200-6400 |
| Tanner stage II, boys | 2300-6300 |
| Tanner stage II, girls | 2800-6900 |
| Tanner stage III, boys | 3100-8900 |
| Tanner stage III, girls | 3900-9400 |
| Tanner stage IV, boys | 3700-8700 |
| Tanner stage IV, girls | 3300-8100 |
| Tanner stage V, boys | 2600-8600 |
| Tanner stage V, girls | 2700-9100 |
ARUP gives one range for both sexes by age; Tanner-stage ranges for children are given separately for boys and girls.
Labcorp gives separate ranges for men and women; ARUP gives one range for both sexes by age, plus Tanner-stage ranges for children. Quest (test 34458) does not publish a range and reports it on the lab report instead.
What raises it
| Factor | How | How much |
|---|---|---|
| Growth hormone (excess or treatment)Hormone | GH increases every part of the IGF-1/IGFBP-3/acid-labile subunit complex. | All 18 untreated acromegaly patients were elevated (4,186-10,026 µg/L). In GH-deficient children, 6 months of GH raised it from 1.3 to 2.7 mg/L. [10] [11] [12] |
| Childhood and pubertyPhysiology | Levels are low at birth, rise through childhood and peak at puberty, which is why ranges are set by age. | Levels rose threefold from early childhood to puberty in the original radioimmunoassay study. [3] [4] |
| Kidney failure (fragments)Condition | Fragments of IGFBP-3 that can no longer bind IGF-1 build up when the kidneys clear them poorly. Standard assays count them, so total IGFBP-3 reads high while the working protein is normal. | No published magnitude [3] [13] |
| Excess thyroid hormoneHormone | IGFBP-3 was higher in overactive thyroid disease and rose with free T4 and T3, without a change in GH. | No published magnitude [5] |
| Late pregnancyPhysiology | A mild elevation was seen in the third trimester in the original radioimmunoassay study. | No published magnitude [4] |
| GH-releasing peptidesPeptide | GH secretagogues and GHRH analogs make the pituitary release more GH. See the peptide table below. | 3,273 vs 2,604 ng/mL on placebo (MK-677, 25 mg/day for a week) [14] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Growth hormone deficiencyCondition | Without enough GH, the liver makes less of the complex. | 133 of 137 GH-deficient patients were below the 5th percentile in the 1990 radioimmunoassay study. [3] |
| GH insensitivity (Laron syndrome)Condition | A faulty GH receptor blocks the GH signal, and giving GH does not correct it. | Median 0.53 mg/L, every patient below the 5th percentile for age (27 patients) [15] |
| Fasting and malnutritionNutrition | IGFBP-3 falls with low food intake. Children with long-term calorie deficiency (marasmus) had lower levels than healthy children. | -16% after a 3-day fast [3] [16] |
| Anorexia nervosaCondition | IGFBP-3 in the large complex was low and returned to normal after partial weight recovery. | No published magnitude [17] |
| Liver diseaseCondition | Levels are low when liver function is impaired, consistent with the liver being a major source. | No published magnitude [3] [2] |
| Poorly controlled diabetesCondition | Levels were below normal in people with poorly controlled diabetes. | 40% below normal in the original radioimmunoassay study [4] |
| Underactive thyroidHormone | Patients made hypothyroid by antithyroid treatment had lower IGFBP-3 than healthy controls. | No published magnitude [5] |
| Somatostatin analogsMedication | Lanreotide lowers GH and, with it, IGFBP-3. See the peptide table below. | No published magnitude [18] |
Peptides that affect IGFBP-3
How each peptide in our library has been shown to affect IGFBP-3, strongest evidence first. "No clear effect" means IGFBP-3 was measured and did not change.
| Peptide | Effect on IGFBP-3 | Size of effect | Evidence |
|---|---|---|---|
| Anamorelin | Raises | +0.43 µg/mL vs placebo (meta-analysis of 5 trials, 1,331 people with cancer; results varied widely between trials)Studied for cancer-related weight and muscle loss (cachexia). [19] | Human trials |
| GHRH (1-29) | Raises | IGFBP-3 rose within 2 weeks of nightly injections (10 µg/kg, P < 0.001) and stayed up for 12 weeksTested as the analog [Nle27]GHRH(1-29) in 19 adults aged 55-71, after 4 weeks of placebo injections. [20] | Human trials |
| GHRP-2 | Raises | Brought low IGFBP-3 back to normal in men with prolonged critical illness (5-day IV infusion, 1 µg/kg/h)Studied in prolonged critical illness, where IGFBP-3 is suppressed, so this shows recovery to normal rather than a rise above it. [21] | Human trials |
| MK-677 (Ibutamoren) | Raises | 3,273 vs 2,604 ng/mL on placebo, averaged over the last 5 days of a week of 25 mg/day (8 healthy adults on a calorie-restricted diet)Oral GH secretagogue (ibutamoren). In obese men, 8 weeks of 25 mg/day also raised IGFBP-3 significantly versus placebo, and it rose within 4 days in GH-deficient young men. [14] [22] [23] | Human trials |
| Tesamorelin | Raises | +0.4 vs -0.1 mg/L on placebo after 12 weeks (2 mg/day, adults with type 2 diabetes)FDA-approved GHRH analog. The rise was significant for 2 mg versus placebo; the overall three-group comparison was not (P = 0.12). [24] | Human trials |
| Lanreotide | Lowers | Statistically significant fall in acromegaly patients treated before surgery (104 patients); a "minor" fall over 4 days after angioplastySomatostatin analog. In acromegaly, IGF-1 is the better marker of control: in one study IGF-1 separated active acromegaly from healthy people better than IGFBP-3 (AUC 0.95 vs 0.89). [18] [25] [26] | Human trials |
| Hexarelin | No clear effect | No significant change in serum IGFBP-3 over 16 weeks of twice-daily injections (P = 0.74)IGF-I did not change either, while the GH response to hexarelin weakened during treatment. [27] | Human trials |
| Leptin | No clear effect | No change in IGF binding proteins during 2 months of r-metHuLeptin (7 men with HIV-related lipoatrophy) or with metreleptin during fasting and hypothalamic amenorrheaMeasured as recombinant leptin (metreleptin) in people with low leptin. [28] [29] | Human trials |
| Sermorelin | No clear effect | No change in IGFBP-3 after 6 weeks of single nightly injections (2 mg, 11 men aged 64-76)Only once-nightly dosing has been measured. The same study saw no IGF-I rise either, while twice-daily dosing raised IGF-I in a separate trial. [30] [31] | Human trials |
| IGF-1 LR3 | Lowers | Plasma IGFBP-3 fell during a 4-day infusion in pigs (180 µg/kg/day); IGF binding proteins also fell in guinea pigs over 7 daysAn IGF-1 analog that binds poorly to IGF binding proteins. In pigs it also suppressed GH, which the authors suggest may explain the drop. [32] [33] | Animal studies |
| Ipamorelin | No clear effect | No change in IGF binding proteins (adult female rats, 15 days)A selective GH secretagogue. Bone growth increased in the same rats. No human IGFBP-3 data have been published. [34] | Animal studies |
What high or low results can mean
A high result
A result above the range for your age at your lab usually reflects more growth hormone activity, but IGFBP-3 is less specific than IGF-1.
- Acromegaly (a GH-secreting pituitary tumor)
- Growth hormone treatment or a GH-releasing peptide (see the peptide table)
- Kidney failure, where inactive fragments build up
- Puberty, which raises it naturally
A low result
A low result can point to growth hormone deficiency, but a normal result does not rule it out.
- Growth hormone deficiency
- GH insensitivity (Laron syndrome)
- Fasting or malnutrition
- Liver disease
- Underactive thyroid
How the test works
| Sample | Serum. Labcorp asks for 1 mL in a red-top or gel-barrier tube; ARUP accepts serum or plasma (0.5 mL). |
|---|---|
| Fasting | Neither Labcorp nor ARUP lists fasting. Labcorp asks you to stop high-dose biotin at least 72 hours before the draw, because biotin can interfere with its assay. |
| Timing | IGFBP-3 stays constant over 24 hours, so the time of day does not matter. |
| Lab differences | Labs use different assays and report different ranges (Labcorp in µg/L, ARUP in ng/mL, which are numerically the same). In kidney disease, standard assays also count inactive fragments. Repeat tests on the same lab if you want to compare them. |
| Retesting | IGFBP-3 responds slowly to growth hormone. In GH-deficient children it doubled over 6 months of GH treatment. |
| Labcorp order code | 140152: Insulin-like Growth Factor-binding Protein 3 (IGFBP-3) |
| ARUP Laboratories order code | 0070060: IGF Binding Protein 3 |
| Quest Diagnostics order code | 34458: IGF Binding Protein-3 (IGFBP-3) (range given on the lab report) |
| LOINC codes |
|
History
IGFBP-3 was purified and given its first assay in 1986. Its value as a growth-hormone test rose in the 1990s and was re-weighed against IGF-1 later.
- 1986Baxter and Martin purify the growth hormone-dependent IGF binding protein from human plasma and measure its tight binding to IGF-I and IGF-II. [6]
- 1986Baxter and Martin publish the first radioimmunoassay for it, showing a 2.2-fold rise in acromegaly and a 50-80% fall in GH deficiency. [4]
- 1990Blum and colleagues develop a specific radioimmunoassay and report it as an excellent screening test for GH deficiency (sensitivity 0.97, specificity 0.95). [38] [3]
- 1994Baxter reviews the six IGF binding proteins, naming IGFBP-3 as the main circulating one, forming a three-part complex with the acid-labile subunit. [1]
- 2015A meta-analysis of 12 studies finds IGFBP-3 detects only half of GH-deficient patients (sensitivity 0.50), placing it as an aid to stimulation testing rather than a stand-alone test. [36]
FAQ
What is the IGFBP-3 test used for?
It is used in the investigation of growth hormone deficiency, acromegaly and hypopituitarism, and to monitor growth hormone treatment, usually alongside IGF-1.
Sources: [2]
Can IGFBP-3 alone diagnose growth hormone deficiency?
No. Across 12 studies it picked up only half of GH-deficient patients (sensitivity 0.50, specificity 0.79). It is best used as an aid alongside a GH stimulation test.
Sources: [36]
Why is IGFBP-3 measured together with IGF-1?
IGFBP-3 is the main carrier of IGF-1: with the acid-labile subunit it holds 75-90% of circulating IGF-1. Measuring both shows how much carrier is available, and the IGF-1 to IGFBP-3 ratio is higher in acromegaly than in healthy adults.
Does IGFBP-3 change with age?
Yes. It is low at birth, peaks at puberty and falls slowly through adult life. Labcorp's range for women aged 21-25 is 2,855-6,559 ng/mL, and for women aged 76-80 it is 1,950-5,490 ng/mL.
Do I need to fast before an IGFBP-3 test?
Neither Labcorp nor ARUP lists fasting, and IGFBP-3 stays constant over 24 hours. A fast of several days does lower it (by 16% after 3 days), and Labcorp asks you to stop high-dose biotin 72 hours before the draw.
Why is my IGFBP-3 high if I have kidney disease?
In kidney disease, fragments of IGFBP-3 that no longer bind IGF-1 build up. Standard assays count them, so total IGFBP-3 reads high while the working protein is normal.
Is IGFBP-3 useful for acromegaly?
It is usually high: all 18 untreated patients in one study were elevated. But values overlap with healthy people in many patients, and IGF-1 separates active acromegaly from health better (AUC 0.95 vs 0.89).
Can peptides raise IGFBP-3?
Some can. MK-677 (Ibutamoren) raised it to 3,273 ng/mL vs 2,604 on placebo within a week, and Tesamorelin raised it by 0.4 mg/L over 12 weeks. Hexarelin left it unchanged over 16 weeks. The table above lists every peptide we cover.
What is the IGF-1 to IGFBP-3 ratio?
It compares IGF-1 with its main carrier. In healthy adults the ratio falls with age, and it is clearly higher in acromegaly, although it still overlaps with healthy values in some patients.
Does biotin affect the result?
It can. Labcorp warns that high-dose biotin supplements interfere with its assay and asks patients to stop biotin at least 72 hours before the sample is taken.
Sources: [2]
Why do labs give different numbers?
Each lab uses its own assay and reference group. Labcorp's range for men aged 21-25 is 2,753-6,361 ng/mL, while ARUP's range for adults aged 21-25 is 3,400-7,800 ng/mL. Compare results only against the range on your own report.
Does thyroid function affect IGFBP-3?
Yes. It was higher in people with overactive thyroids and lower in people made hypothyroid, and it rose with thyroid hormone levels independently of growth hormone.
Sources: [5]
Does estrogen therapy change IGFBP-3?
In a 6-month randomized trial in postmenopausal women, neither oral nor skin-patch estradiol changed IGFBP-3 compared with placebo, even though oral estradiol lowered IGF-1.
Sources: [40]
References
- Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 1994;42(4-5):140-4. PMID 7532612
- Labcorp. Test 140152: Insulin-like Growth Factor-binding Protein 3 (IGFBP-3). Reference intervals, specimen requirements, methodology, limitations and LOINC map. labcorp.com/tests/140152/insulin-like-growth-factor-binding-protein-3-igfbp-3
- Blum WF, Ranke MB. Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res. 1990;33 Suppl 4:31-7. PMID 1700965
- Baxter RC, Martin JL. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 1986;78(6):1504-12. PMID 2431001
- Inukai T, Takanashi K, Takebayashi K, et al. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases. Horm Metab Res. 1999;31(10):576-9. PMID 10596968
- Martin JL, Baxter RC. Insulin-like growth factor-binding protein from human plasma. Purification and characterization. J Biol Chem. 1986;261(19):8754-60. PMID 3722172
- INCRELEX (mecasermin) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce
- Guler HP, Zapf J, Schmid C, et al. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh). 1989;121(6):753-8. PMID 2558477
- ARUP Laboratories. Test 0070060: IGF Binding Protein 3. Laboratory Test Directory: reference intervals, Tanner-stage intervals, specimen requirements and methodology. ltd.aruplab.com/Tests/Pub/0070060
- Grinspoon S, Clemmons D, Swearingen B, et al. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab. 1995;80(3):927-32. PMID 7533774
- Qin S, Shi Y, Deng J. Diagnostic value of serum insulin-like growth factor binding protein-3 in children with or without growth hormone deficiency. Chin Med Sci J. 2002;17(3):160-3. PMID 12901539
- Laursen T, Flyvbjerg A, Jørgensen JO, et al. Stimulation of the 150-kilodalton insulin-like growth factor-binding protein-3 ternary complex by continuous and pulsatile patterns of growth hormone (GH) administration in GH-deficient patients. J Clin Endocrinol Metab. 2000;85(11):4310-4. PMID 11095473
- Büscher AK, Büscher R, Pridzun L, et al. Functional and total IGFBP3 for the assessment of disorders of the GH/IGF1 axis in children with chronic kidney disease, GH deficiency, or short stature after SGA status at birth. Eur J Endocrinol. 2012;166(5):923-31. PMID 22318747
- Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-5. PMID 9467534
- Savage MO, Blum WF, Ranke MB, et al. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab. 1993;77(6):1465-71. PMID 7505286
- Haspolat K, Ece A, Gürkan F, et al. Relationships between leptin, insulin, IGF-1 and IGFBP-3 in children with energy malnutrition. Clin Biochem. 2007;40(3-4):201-5. PMID 17208213
- Støving RK, Hangaard J, Hagen C, et al. Low levels of the 150-kD insulin-like growth factor binding protein 3 ternary complex in patients with anorexia nervosa: effect of partial weight recovery. Horm Res. 2003;60(1):43-8. PMID 12792153
- Lucas T, Astorga R, Catalá M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf). 2003;58(4):471-81. PMID 12641631
- Rezaei S, de Oliveira LC, Ghanavati M, et al. The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials. J Oncol Pharm Pract. 2023;29(7):1725-1735. PMID 37525932
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. PMID 9141536
- Van den Berghe G, Baxter RC, Weekers F, et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf). 2002;56(5):655-69. PMID 12030918
- Chapman IM, Pescovitz OH, Murphy G, et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J Clin Endocrinol Metab. 1997;82(10):3455-63. PMID 9329386
- Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9. PMID 9467542
- Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PMID 28617838
- Frystyk J, Skjaerbaek C, Alexander N, et al. Lanreotide reduces serum free and total insulin-like growth factor-I after angioplasty. Circulation. 1996;94(10):2465-71. PMID 8921789
- Páramo C, Fluiters E, de la Fuente J, et al. Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism. 2001;50(9):1117-21. PMID 11555849
- Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-9. PMID 9589671
- Brennan AM, Lee JH, Tsiodras S, et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol. 2009;160(2):173-6. PMID 19029226
- Pilitsi E, Peradze N, Perakakis N, et al. Circulating levels of the components of the GH/IGF-1/IGFBPs axis total and intact IGF-binding proteins (IGFBP) 3 and IGFBP 4 and total IGFBP 5, as well as PAPPA, PAPPA2 and Stanniocalcin-2 levels are not altered in response to energy deprivation and/or metreleptin administration in humans. Metabolism. 2019;97:32-39. PMID 31103608
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PMID 9005976
- Corpas E, Harman SM, Piñeyro MA, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5. PMID 1379256
- Dunaiski V, Dunshea FR, Walton PE, et al. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol. 1997;155(3):559-65. PMID 9488001
- Conlon MA, Tomas FM, Owens PC, et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-53. PMID 7561636
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. PMID 10373343
- de Herder WW, van der Lely AJ, Janssen JA, et al. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol (Oxf). 1995;43(4):501-5. PMID 7586626
- Shen Y, Zhang J, Zhao Y, et al. Diagnostic value of serum IGF-1 and IGFBP-3 in growth hormone deficiency: a systematic review with meta-analysis. Eur J Pediatr. 2015;174(4):419-27. PMID 25213432
- LOINC 2483-6: Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/2483-6
- Blum WF, Ranke MB, Kietzmann K, et al. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990;70(5):1292-8. PMID 1692331
- Juul A, Main K, Blum WF, et al. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf). 1994;41(1):85-93. PMID 7519529
- Sonnet E, Lacut K, Roudaut N, et al. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf). 2007;66(5):626-31. PMID 17492948
Educational information, not medical advice. Lab ranges and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.